{"id":"W4306757577","doi":"10.1016/j.kint.2022.09.017","title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","year":2022,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Placebo; Medicine; Renal function; Clinical endpoint; Urology; Budesonide; Adverse effect; Internal medicine; Randomized controlled trial; Clinical trial; Nephropathy; Kidney disease; Gastroenterology; Corticosteroid; Pathology; Endocrinology; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009593009,0.0002029744,0.0008824801,0.0001235172,0.0001293352,0.00001436234,0.000275944,0.00005402821,0.00023461],"category_scores_gemma":[0.001896003,0.0001111187,0.0009305845,0.0002048145,0.00009841445,0.00006120429,0.00008050894,0.0001067141,0.000001373525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002303827,"about_ca_system_score_gemma":0.0006677632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007272352,"about_ca_topic_score_gemma":0.0000292275,"domain_scores_codex":[0.9971181,0.000311391,0.001299153,0.0002592718,0.0008545406,0.0001575538],"domain_scores_gemma":[0.9966404,0.001108697,0.001090917,0.0004303356,0.0006365896,0.00009299213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9866551,0.004007261,0.0002208607,0.00003953413,0.002282982,0.000001403431,0.0008100753,0.001707941,0.001538466,0.0001257028,0.001360189,0.001250454],"study_design_scores_gemma":[0.9447971,0.0009449705,0.0008317197,0.0001507683,0.00133905,0.000003221829,0.0001550718,0.04323283,0.001640361,0.00008057968,0.006734848,0.00008949289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708037,0.002000126,0.0004953676,0.00548353,0.001638138,0.01117003,0.008031698,0.00002224081,0.0003551406],"genre_scores_gemma":[0.9932997,0.0005527874,0.0003827758,0.0002534416,0.0002149347,0.001979148,0.002691885,0.00002114182,0.0006041363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04185805,"threshold_uncertainty_score":0.4531288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0392503578415708,"score_gpt":0.3058367754631991,"score_spread":0.2665864176216283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}